Abstract: The present invention relates to pyridoxine (vitamin B6) derived compounds of formula (I), pharmaceutically acceptable salts, or solvates thereof, wherein R1, R2, R4, A, L B1 and B2 are as defined in the specification, and pharmaceutical compositions comprising the compounds. Compounds of formula (I) inhibit Human Immunodeficiency Virus (HIV)-integrase enzyme and are useful for preventing and treating HIV infection and AIDS.

Abstract: A method may include receiving, via a first network, a message identifying an event, where the event is associated with an entity, and the event is destined for at least one user. The method may include determining, by a processor of a computing device, a type of the event, and accessing, by the processor, a user profile associated with a first user of the at least one user, where the user profile associates the first user with the entity. The method may include determining, by the processor, a communication channel for delivering information associated with the event to the first user, where the user profile includes an association between the communication channel and the type of the event. The method may include forwarding, via a second network, to the first user, the information associated with the event, where the information associated with the event is forwarded via the communication channel.

Abstract: A system and method for optimization of media objects for delivery to one of a plurality of mobile communication devices of different types and rendering thereon. In particular, the media objects are optimized according to the mobile device's characteristics to ensure efficient delivery and optimal rendering thereon. For this purpose, an optimized output of the media object is determined at a first stage. At a subsequent stage, based on the mobile device type, the characteristics of the object to be delivered are then adjusted to conform to those of the predetermined optimized output, thus ensuring that the rendering of the optimized media object on the mobile device output is of high quality.

Abstract: The present disclosure describes, among other things, a method. The method may include receiving a communication from a user through a first communication channel. The method may include matching the communication with a workflow based on a correlation between the workflow and an indicia associated with the first communication channel and the user. The method may include processing the communication according to a first step in the workflow.

Abstract: A system and method for optimisation of media objects for delivery to one of a plurality of mobile communication devices of different types and rendering thereon. In particular, the media objects are optimised according to the mobile device's characteristics to ensure efficient delivery and optimal rendering thereon. For this purpose, an optimised output of the media object is determined at a first stage. At a subsequent stage, based on the mobile device type, the characteristics of the object to be delivered are then adjusted to conform to those of the predetermined optimised output, thus ensuring that the rendering of the optimised media object on the mobile device output is of high quality.

Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Abstract: A system and method for optimization of media objects for delivery to one of a plurality of mobile communication devices of different types and rendering thereon. In particular, the media objects are optimised according to the mobile device's characteristics to ensure efficient delivery and optimal rendering thereon. For this purpose, an optimised output of the media object is determined at a first stage. At a subsequent stage, based on the mobile device type, the characteristics of the object to be delivered are then adjusted to conform to those of the predetermined optimised output, thus ensuring that the rendering of the optimised media object on the mobile device output is of high quality.

Abstract: The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Abstract: The present invention relates to pyridoxine (vitamin B6) derived compounds of formula (I), pharmaceutically acceptable salts, or solvates thereof, wherein R1, R2, R4, A, L B1 and B2 are as defined in the specification, and pharmaceutical compositions comprising the compounds. Compounds of formula (I) inhibit Human Immunodeficiency Virus (HIV)-integrase enzyme and are useful for preventing and treating HIV infection and AIDS.

Abstract: The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Abstract: The invention encompasses a series of bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents.

Abstract: A system and method for optimisation of media objects for delivery to one of a plurality of mobile communication devices of different types and rendering thereon. In particular, the media objects are optimised according to the mobile device's characteristics to ensure efficient delivery and optimal rendering thereon. For this purpose, an optimised output of the media object is determined at a first stage. At a subsequent stage, based on the mobile device type, the characteristics of the object to be delivered are then adjusted to conform to those of the predetermined optimised output, thus ensuring that the rendering of the optimised media object on the mobile device output is of high quality.

Abstract: The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Abstract: Benzimidazole derivatives having the general formula I are provided. These compounds are useful as tyrosine kinase inhibitors, especially for the treatment of cancer.

Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents.

Abstract: The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents.

Abstract: The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.